120 related articles for article (PubMed ID: 26524854)
1. [Hormonal Receptor and HER2 Analyses for Breast Cancer Using Cell Blocks in Routine Work: Experience at Our Institution].
Nishimura R
Rinsho Byori; 2015 Mar; 63(3):319-21. PubMed ID: 26524854
[TBL] [Abstract][Full Text] [Related]
2. Comparison Between HER2, Estrogen Receptors and Progesterone Receptors in Primary Breast Carcinomas and Matched Lymph Node Metastases.
Desouki MM; Atta IS; Wolff DJ; Self SE
Turk Patoloji Derg; 2016; 32(3):178-85. PubMed ID: 27562392
[TBL] [Abstract][Full Text] [Related]
3. Benefits of using the cell block method to determine the discordance of the HR/HER2 expression in patients with metastatic breast cancer.
Nakayama Y; Nakagomi H; Omori M; Inoue M; Takahashi K; Maruyama M; Takano A; Furuya K; Amemiya K; Ishii E; Oyama T
Breast Cancer; 2016 Jul; 23(4):633-9. PubMed ID: 25968348
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the HER2 and Hormone Receptor Status in Metastatic Breast Cancer Using Cell Blocks: A Multi-Institutional Study.
Nishimura R; Murata Y; Mori K; Yamashiro K; Kuraoka K; Ichihara S; Taguchi K; Suzuki H; Ito M; Yamashita N
Acta Cytol; 2018; 62(4):288-294. PubMed ID: 29763896
[TBL] [Abstract][Full Text] [Related]
5. Breast Cancer Biomarkers: Challenges in Routine Estrogen Receptor, Progesterone Receptor, and HER2/neu Evaluation.
Jorns JM
Arch Pathol Lab Med; 2019 Dec; 143(12):1444-1449. PubMed ID: 31373514
[TBL] [Abstract][Full Text] [Related]
6. The Actual Role of Receptors as Cancer Markers, Biochemical and Clinical Aspects: Receptors in Breast Cancer.
Brennan M; Lim B
Adv Exp Med Biol; 2015; 867():327-37. PubMed ID: 26530375
[TBL] [Abstract][Full Text] [Related]
7. Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer.
Vera-Badillo FE; Chang MC; Kuruzar G; Ocana A; Templeton AJ; Seruga B; Goldstein R; Bedard PL; Tannock IF; Amir E
J Clin Pathol; 2015 Oct; 68(10):839-43. PubMed ID: 26076967
[TBL] [Abstract][Full Text] [Related]
8. Oncotype DX test on unequivocally HER2-positive cases: potential for harm.
Bhargava R; Dabbs DJ
J Clin Oncol; 2012 Feb; 30(5):570-1. PubMed ID: 22231038
[No Abstract] [Full Text] [Related]
9. The association of infrared imaging findings of the breast with hormone receptor and human epidermal growth factor receptor 2 status of breast cancer.
Wang J; Shih TT; Yen RF; Lu YS; Chen CY; Mao TL; Lin CH; Kuo WH; Tsai YS; Chang KJ; Chien KL
Acad Radiol; 2011 Feb; 18(2):212-9. PubMed ID: 21126889
[TBL] [Abstract][Full Text] [Related]
10. Highly reproducible results of breast cancer biomarkers when analysed in accordance with national guidelines - a Swedish survey with central re-assessment.
Ekholm M; Grabau D; Bendahl PO; Bergh J; Elmberger G; Olsson H; Russo L; Viale G; Fernö M
Acta Oncol; 2015 Jul; 54(7):1040-8. PubMed ID: 25959664
[TBL] [Abstract][Full Text] [Related]
11. Estimation of hormone receptor status and HER2 in cytologic cell blocks from breast cancer using the novel rabbit monoclonal antibodies (SP1, SP2, and SP3).
Nassar A; Cohen C; Siddiqui M
Diagn Cytopathol; 2009 Dec; 37(12):865-70. PubMed ID: 19530101
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the oestrogen and progesterone receptor status in primary breast carcinomas as evaluated by immunohistochemistry and immunocytochemistry: a consecutive series of 267 patients.
Domanski AM; Monsef N; Domanski HA; Grabau D; Fernö M
Cytopathology; 2013 Feb; 24(1):21-5. PubMed ID: 22783929
[TBL] [Abstract][Full Text] [Related]
13. Standardizing slide-based assays in breast cancer: hormone receptors, HER2, and sentinel lymph nodes.
Ross JS; Symmans WF; Pusztai L; Hortobagyi GN
Clin Cancer Res; 2007 May; 13(10):2831-5. PubMed ID: 17504980
[TBL] [Abstract][Full Text] [Related]
14. Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study.
Puig-Vives M; Sánchez MJ; Sánchez-Cantalejo J; Torrella-Ramos A; Martos C; Ardanaz E; Chirlaque MD; Perucha J; Díaz JM; Mateos A; Machón M; Marcos-Gragera R
Gynecol Oncol; 2013 Sep; 130(3):609-14. PubMed ID: 23747837
[TBL] [Abstract][Full Text] [Related]
15. Validated biomarkers: The key to precision treatment in patients with breast cancer.
Duffy MJ; O'Donovan N; McDermott E; Crown J
Breast; 2016 Oct; 29():192-201. PubMed ID: 27521224
[TBL] [Abstract][Full Text] [Related]
16. Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer.
Hammond ME; Hayes DF; Wolff AC
J Clin Oncol; 2011 May; 29(15):e458. PubMed ID: 21502545
[No Abstract] [Full Text] [Related]
17. Reliability of Her2/neu, estrogen receptor, and progesterone receptor testing by immunohistochemistry on cell block of FNA and serous effusions from patients with primary and metastatic breast carcinoma.
Shabaik A; Lin G; Peterson M; Hasteh F; Tipps A; Datnow B; Weidner N
Diagn Cytopathol; 2011 May; 39(5):328-32. PubMed ID: 21488175
[TBL] [Abstract][Full Text] [Related]
18. Predictive markers in breast cancer: An update on ER and HER2 testing and reporting.
Calhoun BC; Collins LC
Semin Diagn Pathol; 2015 Sep; 32(5):362-9. PubMed ID: 25770732
[TBL] [Abstract][Full Text] [Related]
19. Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients.
Aktas B; Müller V; Tewes M; Zeitz J; Kasimir-Bauer S; Loehberg CR; Rack B; Schneeweiss A; Fehm T
Gynecol Oncol; 2011 Aug; 122(2):356-60. PubMed ID: 21605893
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
Parise CA; Bauer KR; Brown MM; Caggiano V
Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
